Human Antichimeric Antibody in Children and Young Adults with Inflammatory Bowel Disease Receiving Infliximab

Abstract

In children and adolescents with IBD, HACA formation is related to IR and to the duration of response to treatment. Immunomodulatory agents seem to have a protective role against development of HACA or high titers of antibodies. The interval between infusions does not influence the development of HACA.